Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-02-13 pm EST			5-day change	1st Jan Change
121.41 ^USD	+1.82%		-0.43%	+15.34%

Feb. 13	Merck Shares Rise After Deutsche Bank Upgrade	MT
Feb. 13	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid January Consumer Price Inflation Report	MT

Merck Begins Phase 3 Trial of Calderasib With Keytruda QLEX in Non-Small Cell Lung Cancer

Published on 01/07/2026 at 07:50 am EST

MT Newswires

Latest news about Merck & Co., Inc.

Feb. 13	Merck Shares Rise After Deutsche Bank Upgrade	MT
Feb. 13	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid January Consumer Price Inflation Report	MT
Feb. 13	Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115	MT
Feb. 13	Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115	MT
Feb. 12	Merck & Co. Insider Sold Shares Worth $1,214,562, According to a Recent SEC Filing	MT
Feb. 12	Argus Adjusts Price Target on Merck to $130 From $110, Maintains Buy Rating	MT
Feb. 12	Merck Advances Treatment of Bladder and Kidney Cancers with New Data At 2026 ASCO GU Cancers Symposium	CI
Feb. 11	Sector Update: Health Care Stocks Rise Late Afternoon	MT
Feb. 11	Sector Update: Health Care Stocks Advance Wednesday Afternoon	MT
Feb. 11	Sector Update: Health Care	MT
Feb. 11	Daiwa Securities Adjusts PT on Merck & Co. to $120 From $86, Maintains Neutral Rating	MT
Feb. 11	Merck Announces the U.S. Food and Drug Administration Approves KEYTRUDA (Pembrolizumab and Berahyaluronidase Alfa-Pmph) and KEYTRUDA QLEX	CI
Feb. 11	Agilent's Ovarian Cancer Diagnostic Test Receives FDA Clearance	MT
Feb. 11	Merck Says US FDA Approves Keytruda Combination in Platinum-Resistant Ovarian Cancer	MT
Feb. 10	Merck & Co. Insider Sold Shares Worth $1,202,844, According to a Recent SEC Filing	MT

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (20%); - sale of animal health products (9.2%); - other (1.4%). Net sales are distributed geographically as follows: the United States (50.3%), Europe/Middle East/Africa (21.8%), Latin America (5.4%), China (8.6%), Japan (5.1%), Asia/Pacific (4.8%) and other (4%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

Mar. 15 -

More about the company